Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Mark A Wainberg"'
Publikováno v:
Infection, Genetics and Evolution. 46:286-291
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been docume
Publikováno v:
Pathogens and Immunity, Vol 1, Iss 1, Pp 41-67 (2016)
Pathogens & Immunity
Pathogens & Immunity
Since the discovery of the first inhibitors of HIV replication, drug resistance has been a major problem in HIV therapy, due, in part, to the high mutation rate of HIV. Therefore, the development of a predictive animal model is important to identify
Autor:
Daniela Moisi, Peter K. Quashie, Mark A. Wainberg, Thibault Mesplède, Yannan Liu, Maureen Oliveira, Said Hassounah, Bluma G. Brenner, Paul Sandstrom
Publikováno v:
Journal of Virology. 89:12002-12013
We previously showed that the simian immunodeficiency virus SIVmac239 is susceptible to human immunodeficiency virus (HIV) integrase (IN) strand transfer inhibitors (INSTIs) and that the same IN drug resistance mutations result in similar phenotypes
Autor:
Zabrina L. Brumme, Cassandra N. Naphen, Natalie N. Kinloch, Silven Read, David E. Williams, Brendan Bell, Tristan J. Markle, Philip Mwimanzi, Xiaomei T. Kuang, Mark A. Brockman, Ian Tietjen, Mark A. Wainberg, Emmanuelle Wilhelm, Raymond J. Andersen, Phillip Crews, Karen Tenney, Thibault Mesplède
Publikováno v:
Antiviral research. 152
HIV-1 inhibitors that act by mechanisms distinct from existing antiretrovirals can provide novel insights into viral replication and potentially inform development of new therapeutics. Using a multi-cycle HIV-1 replication assay, we screened 252 pure
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:310-316
Clinical studies have shown that integrase strand transfer inhibitors (INSTIs) can be used effectively against HIV-1 infection. To date, no resistance substitution has been found in INSTI-naive patients treated with the new integrase inhibitor dolute
Autor:
Bluma G. Brenner, Agnès Depatureaux, Hannah Koubi, Daniela Moisi, Mark A. Wainberg, Thibault Mesplède, Peter K. Quashie, Maureen Oliveira, Ying-Shan Han, Jean-Christophe Plantier
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:7141-7150
HIV-1 group O (HIV-O) is a rare HIV-1 variant characterized by a high number of polymorphisms, especially in the integrase coding region. As HIV-O integrase enzymes have not previously been studied, our aim was to assess the impact of HIV-O integrase
Autor:
Said Hassounah, Maureen Oliveira, Victor G. Kramer, Susan P. Colby-Germinario, Mark A. Wainberg, Eric Lefebvre, Thibault Mesplède
Publikováno v:
Journal of Antimicrobial Chemotherapy. 70:750-756
Objectives Cenicriviroc is a potent antagonist of the chemokine coreceptors 5 and 2 (CCR5/CCR2) and blocks HIV-1 entry. The CCR5 inhibitor maraviroc has been shown in tissue culture to be able to repel cell-free virions from the cell surface into ext
Autor:
Susan P. Colby-Germinario, Maureen Oliveira, Hongtao Xu, Daniel Rajotte, Richard Bethell, Mark A. Wainberg
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:4515-4526
A W153L substitution in HIV-1 reverse transcriptase (RT) was recently identified by selection with a novel nucleotide-competing RT inhibitor (NcRTI) termed compound A that is a member of the benzo[4,5]furo[3,2,d]pyrimidin-2-one NcRTI family of drugs.
Publikováno v:
Journal des Anti-infectieux. 16:44-49
Resume L’inhibiteur d’integrase dolutegravir (DTG), qui a ete recemment approuve pour le traitement des personnes vivant avec le VIH, un des tres rares medicaments contre le VIH qui n’ait pas conduit a l’emergence de mutations de resistance l
Autor:
Alonso Heredia, Mohammed N. Amin, Steven G. Deeks, Maureen Oliveira, Robert R. Redfield, Charles B. Davis, Mark A. Wainberg, Lai-Xi Wang, Nhut Le
Publikováno v:
AIDS (London, England), vol 28, iss 3
Objective The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhib